Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | BCL2L11 |
| Gene Name: | BCL2L11 |
| Protein Full Name: | Bcl-2-like protein 11 |
| Alias: | Bcl2 interacting mediator of cell death; BCL2 interacting mediator of cell death; Bcl-2 related ovarian death protein; BCL2L11; BCL2-like 11 (apoptosis facilitator); BCL2-like protein 11; Bcl2-like protein 11; BIM; BimEL; BimL; BOD |
| Mass (Da): | 22171 |
| Number AA: | 198 |
| UniProt ID: | O43521 |
| Locus ID: | 10018 |
| COSMIC ID: | BCL2L11 |
| Gene location on chromosome: | 2q13 |
| Cancer protein type: | TSP |
| Effect of cancer mutation on protein: | LOSS |
| Effect of active protein on cancer: | INHIBITS |
| Number of cancer specimens: | 20150 |
| Percent of cancer specimens with mutations: | 0.21 |
| Normal role description: | BC2L11 is a pro-apoptotic protein that responds to various intrinsic stimuli. It is a can bind and interact with both pro-survival and pro-apoptotic members of the Bcl-2 family. It is regulated by ERKs and JNK as well as FOXO-3a and c-JUN. It an important role in neuronal and lymphoctye apoptosis and maintaining hematopoietic homeostasis. Another important role is removal of auto-reactive lymphocytes and prevention of auto-immune disease. In cancer, it has role in apoptosis of cancer cells and overcoming some drug resistances. |
| Commentary on involvement of protein in cancer: | Sanger had no report of any mutations |